{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-335824","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2025-12-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.068479+00:00","generated_at":"2026-05-16T11:59:42.497050+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Verrica appoints Charles Frantzreb to board, grants performance-based options to CEO","bullets":["Charles Frantzreb, Partner at Caligan, appointed to board effective Dec 26, 2025; Class III director term to 2027 annual meeting.","CEO Jayson Rieger granted options for 512,269 shares at $8.21, vesting on stockholder plan amendment and stock price milestones of $15 and $25.","Interim CFO John Kirby granted 10,000 fully vested RSUs on Dec 23, 2025.","Frantzreb designated by Caligan under Securities Purchase Agreement dated Nov 23, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-335824","json":"https://secwatch.observer/filing/0001193125-25-335824.json","markdown":"https://secwatch.observer/filing/0001193125-25-335824.md","text":"https://secwatch.observer/filing/0001193125-25-335824.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525335824/0001193125-25-335824-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525335824/d54232d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:59:42.497050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}